Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI Dose Finding in COPD
NCT01072149Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2010
- Primary completion
- Jul 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone and vilanterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: Time-adjusted Area Under the Curve for 24-hour Serial Forced Expiratory Volume in One Second at Day 28. Started Jan 2010; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01072149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01072149.